Edition:
United Kingdom

Endocyte Inc (ECYT.OQ)

ECYT.OQ on NASDAQ Stock Exchange Global Select Market

9.61USD
6:39pm BST
Change (% chg)

$-0.12 (-1.23%)
Prev Close
$9.73
Open
$9.70
Day's High
$9.95
Day's Low
$9.57
Volume
73,258
Avg. Vol
450,773
52-wk High
$11.54
52-wk Low
$1.17

Select another date:

Mon, Apr 16 2018

BRIEF-Endocyte Says Data Presented At AACR Show That EC17 Penetrates Solid Tumors Within Minutes And Is Retained Due To High Affinity For Folate Receptor

* ENDOCYTE INC - DATA PRESENTED AT AACR SHOW THAT EC17 PENETRATES SOLID TUMORS WITHIN MINUTES AND IS RETAINED DUE TO HIGH AFFINITY FOR FOLATE RECEPTOR Source text for Eikon: Further company coverage:

BRIEF-Endocyte Nominates Dawn Svoronos For Election To Its Board

* ENDOCYTE NOMINATES DAWN SVORONOS FOR ELECTION TO ITS BOARD OF DIRECTORS AND ANNOUNCES OTHER BOARD DEVELOPMENTS

BRIEF-Endocyte Says ‍In Connection With Machado's Election, Board Increased Size To 11 Members​

* ENDOCYTE INC SAYS ‍IN CONNECTION WITH MACHADO'S ELECTION, BOARD INCREASED SIZE OF BOARD FROM 10 TO 11 MEMBERS - SEC FILING​ Source text: (http://bit.ly/2FKviW0) Further company coverage:

BRIEF-Endocyte Announces Proposed Public Offering Of Common Stock

* ENDOCYTE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Endocyte Inc Appoints Patrick Machado To Its Board

* ENDOCYTE APPOINTS PATRICK MACHADO, J.D. TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Endocyte Announces Phase 3 Vision Trial,Provides Update On Corporate Strategy And Reports Q4 And 2017 Financial Results

* ENDOCYTE ANNOUNCES PHASE 3 VISION TRIAL AND PROVIDES UPDATE ON CORPORATE STRATEGY AND REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS

BRIEF-Endocyte And ITM Announce Supply Agreement

* ENDOCYTE AND ITM ANNOUNCE SUPPLY AGREEMENT FOR NO-CARRIER-ADDED LUTETIUM FOR THE PHASE 3 VISION TRIAL

BRIEF-‍Partner Fund Management LP reports a 6.6 pct passive stake in Endocyte as of Nov 6

* ‍Partner Fund Management LP reports a 6.6 percent passive stake in Endocyte Inc as of November 6 - SEC Filing​ Source text: [http://bit.ly/2A4glhH] Further company coverage:

BRIEF-Endocyte Q3 loss per share $0.55

* Q3 loss per share $0.55 Source text for Eikon: Further company coverage:

Select another date: